Ibudilast

Phase 3Small molecule

UUniversity of California, Los Angeles

Ibudilast is one of 119 small molecule programs targeting Methamphetamine Dependence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Methamphetamine DependenceActive, not recruiting

Multiple SclerosisActive, not recruiting

MigraineActive, not recruiting

COVID-19Active, not recruiting

MyelopathyActive, not recruiting

Methamphetamine DependencePhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

MigrainePhase 1

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

MyelopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Ibudilast

UUniversity of California, Los Angeles

Phase 3

2 2

Spikevax

Moderna

Preclinical

21 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Stivarga

Bayer

Preclinical

1 5

Aimovig

Amgen

Preclinical

1 6

Aldactone

Pfizer

Preclinical

1 7

Nexavar

Bayer

Preclinical

1 8

Calciferol

Alnylam Pharmaceuticals

Activella

Aquasol E

NNational Eye Institute (NEI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Myelopathy

NCT04631471

Q4 2027

Phase 2Active, not recruiting

Alcohol Use Disorder

NCT05414240

Clinical

Trials by Indication[1]

Alcohol Use Disorder3 trials

Ibudilast for Treating Alcohol Use Disorder

Active, not recruiting·UUniversity of Pennsylvania·Phase 2·NCT05414240·50 enrolled

Development of Ibudilast for Alcohol Use Disorder

Completed·UUniversity of California, Los Angeles·Phase 1·NCT02025998·24 enrolled

Ibudilast for the Treatment of Alcohol Use Disorder

Completed·UUniversity of California, Los Angeles·Phase 2·NCT03594435·102 enrolled

COVID-192 trials

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

Completed·MMediciNova·Phase 2·NCT04429555·34 enrolled

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Completed·UUniversity Health Network, Toronto·Phase 2/3·NCT05513560·460 enrolled

Methamphetamine Dependence1 trial

Trial of Ibudilast for Methamphetamine Dependence

Completed·UUniversity of California, Los Angeles·Phase 2·NCT01860807·125 enrolled

Migraine1 trial

Ibudilast in the Treatment of Patients With Chronic Migraine.

Completed·PParisa Gazerani·Phase 1·NCT01389193·33 enrolled

Methamphetamine Use1 trial

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

Completed·VVA Office of Research and Development·Phase 2·NCT03341078·176 enrolled

6 more indications

Multiple Sclerosis1 trial

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

Completed·MMediciNova·Phase 2·NCT01982942·255 enrolled

Biomarker1 trial

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

Completed·MMediciNova·Phase 1/2·NCT02714036·35 enrolled

Myelopathy1 trial

Regeneration in Cervical Degenerative Myelopathy

Recruiting·—·Phase 3·NCT04631471·400 enrolled

Headache1 trial

Ibudilast in the Treatment of Medication Overuse Headache

Unknown status·UUniversity of Adelaide·Phase 1/2·NCT01317992·40 enrolled

Withdrawal1 trial

Ibudilast and Withdrawal-Related Dysphoria

Completed·UUniversity of California, Los Angeles·Phase 2·NCT03489850·52 enrolled

Methamphetamine1 trial

Safety Interaction Trial Ibudilast and Methamphetamine

Completed·UUniversity of California, Los Angeles·Phase 1·NCT01217970·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Ibudilast. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibudilast compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibudilast. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, Los Angeles

Ibudilast

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Trials by Indication[1]

Alcohol Use Disorder3 trials

COVID-192 trials

Methamphetamine Dependence1 trial

Migraine1 trial

Methamphetamine Use1 trial

Multiple Sclerosis1 trial

Biomarker1 trial

Myelopathy1 trial

Headache1 trial

Withdrawal1 trial

Methamphetamine1 trial

References

Drug Info

Quick Facts

Related News